READ: Featured Drug Insights: January 2025 - Prime Therapeutics
READ: Featured Drug Insights: January 2025
Your source for all Prime Therapeutics' January 2025 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for January 2025 will keep you informed on what’s trending now.
Released Jan. 31, 2025
Prime provides a quarterly drug pipeline report of anticipated new drugs, deep dives and indications for the following pipelines: traditional, specialty drugs, biosimilars, and gene and cell therapy.
A review of newly approved specialty drugs, recent drug launches and new indications in the last month, this month includes cosibelimab-ipdl (Unloxcyt), crinecerfont (Crenessity), ensartinib (Ensacove) and more.
Released Jan. 30, 2025
Clinical Highlights: January 2025
An overview of clinical insights’ trending topics and timely drug information highlights, this month discusses how shortages of stimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) continue to be reported.
Quarterly Drug Pipeline: January 2025
Dive into clinical insights and competitive intelligence on anticipated drugs in development, so you are well-sourced on the drug pipeline.
Released Jan. 16, 2025
Featuring commentary by Simone Ndujiuba on developments in the oncology space, this installment features a look back on the the most talked about Oncology Insights topics in 2024.
Released Jan. 15, 2025
FDA Decisions Expected for February 2025
A breakdown of FDA decisions expected of new drugs expected to hit the market. This edition covers meningococcal vaccine (MenABCWY), chikungunya vaccine, vimseltinib and more.
Released Jan. 13, 2025
A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are prademagene zamikeracel/ (Abeona) and pariglasgene brecaparvovec / (Ultragenyx).
Providing a clinical deep dive into a select high cost drug in the pipeline. This month’s profile features Tabelecleucel Intravenous (IV) for Epstein-Barr virus-positive (EBV+) post-transplant lymphoproliferative disease (PTLD).
FDA drug recalls
Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go
Alcon is voluntarily recalling one lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25-count to the consumer level. Read more about this recall.
All brand names are property of their respective owners.